novonorm repaglinide tablet 2mg per tablet 30tablets per carton

Description

Indication & Scope

FuLaiDi®/NovoNorm® is a prescription meglitinide antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is suitable for patients whose blood glucose remains inadequately controlled despite lifestyle modification and may be used alone or in combination with metformin. Repaglinide provides rapid, short-acting stimulation of insulin secretion and is particularly effective for controlling postprandial blood glucose excursions.

Mechanism: Repaglinide stimulates insulin release by binding to ATP-sensitive potassium channels on pancreatic β-cells, causing membrane depolarization, calcium influx, and rapid insulin secretion.
Drug class: Meglitinide (non-sulfonylurea insulin secretagogue).
Clinical use: Treatment of adults with type 2 diabetes mellitus as monotherapy or in combination with metformin when glycemic control is inadequate. Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Specification

Generic Name	Repaglinide Tablets
Brand Name	FuLaiDi®; NovoNorm®
Ingredient	Repaglinide
Dosage Form	Tablet
Package	0.5 mg/tablet, 60 tablets/carton 2.0 mg/tablet, 30 tablets/carton
Conditions Treated	Glycemic control in adults with type 2 diabetes mellitus
Taboos	Hypersensitivity to repaglinide; type 1 diabetes mellitus; diabetic ketoacidosis; severe hepatic impairment; concomitant use with gemfibrozil
Place of origin	China; Germany
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C in a dry place, protected from light and moisture.
Manufacturer	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Boehringer Ingelheim Pharma GmbH & Co.KG
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H20103638; HJ20171160
Approval Date	May 28, 2025; January 30, 2022
Shelf Life	24 months

How to use ?

Recommended Dose: The usual starting dose is 0.5 mg before each main meal. The dose should be individualized according to blood glucose response. The maximum single dose is 4 mg, and the maximum total daily dose is 16 mg.

Time: Take within 30 minutes before meals, preferably immediately before eating.

Instructions for use: Swallow the tablet with water before each main meal. Skip the dose if a meal is skipped to reduce the risk of hypoglycemia. Continue diet and exercise throughout treatment, and monitor blood glucose regularly to adjust the dose when necessary.

Interaction: The glucose-lowering effect may be enhanced by metformin, insulin, DPP-4 inhibitors, SGLT2 inhibitors, salicylates, and β-blockers, while corticosteroids, thiazide diuretics, thyroid hormones, and oral contraceptives may reduce its efficacy. Concomitant use with gemfibrozil is contraindicated because it markedly increases repaglinide exposure and the risk of severe hypoglycemia.

Side effects: Common adverse reactions include hypoglycemia, abdominal pain, diarrhea, nausea, constipation, headache, dizziness, and upper respiratory tract infection. Less common reactions include elevated liver enzymes, visual disturbances, hypersensitivity reactions, and skin rash.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support